Header

UZH-Logo

Maintenance Infos

A single 60.000 IU dose of erythropoietin does not improve short-term aerobic exercise performance in healthy subjects: a randomized, double-blind, placebo-controlled crossover trial


Haider, Thomas; Diaz, Victor; Albert, Jamie; Alvarez-Sanchez, Maria; Thiersch, Markus; Maggiorini, Marco; Hilty, Matthias P; Spengler, Christina M; Gassmann, Max (2020). A single 60.000 IU dose of erythropoietin does not improve short-term aerobic exercise performance in healthy subjects: a randomized, double-blind, placebo-controlled crossover trial. Frontiers in Physiology, 11:537389.

Abstract

Erythropoietin (EPO) boosts exercise performance through increase in oxygen transport capacity following regular administration of EPO but preclinical study results suggest that single high dose of EPO also may improve exercise capacity. Twenty-nine healthy subjects (14 males/15 females; age: 25 ± 3 years) were included in a randomized, double-blind, placebo-controlled crossover study to assess peak work load and cardiopulmonary variables during submaximal and maximal cycling tests following a single dose of 60.000 IU of recombinant erythropoietin (EPO) or placebo (PLA). Submaximal exercise at 40%/60% of peak work load revealed no main effect of EPO on oxygen uptake (27.9 ± 8.7 ml min-1⋅kg-1/ 37.1 ± 13.2 ml min-1⋅kg-1) versus PLA (25.2 ± 3.7 ml min-1⋅kg-1/ 33.1 ± 5.3 ml min-1⋅kg-1) condition (p = 0.447/p = 0.756). During maximal exercise peak work load (PLA: 3.5 ± 0.6 W⋅kg-1 vs. EPO: 3.5 ± 0.6 W kg-1, p = 0.892) and peak oxygen uptake (PLA: 45.1 ± 10.4 ml⋅min-1 kg-1 vs. EPO: 46.1 ± 14.2 ml⋅min-1 kg-1, p = 0.344) reached comparable values in the two treatment conditions. Other cardiopulmonary variables (ventilation, cardiac output, heart rate) also reached similar levels in the two treatment conditions. An interaction effect was found between treatment condition and sex resulting in higher peak oxygen consumption (p = 0.048) and ventilation (p = 0.044) in EPO-treated males. In conclusion, in a carefully conducted study using placebo-controlled design the present data failed to support the hypothesis that a single high dose of EPO has a measurable impact on work capacity in healthy subjects.

Abstract

Erythropoietin (EPO) boosts exercise performance through increase in oxygen transport capacity following regular administration of EPO but preclinical study results suggest that single high dose of EPO also may improve exercise capacity. Twenty-nine healthy subjects (14 males/15 females; age: 25 ± 3 years) were included in a randomized, double-blind, placebo-controlled crossover study to assess peak work load and cardiopulmonary variables during submaximal and maximal cycling tests following a single dose of 60.000 IU of recombinant erythropoietin (EPO) or placebo (PLA). Submaximal exercise at 40%/60% of peak work load revealed no main effect of EPO on oxygen uptake (27.9 ± 8.7 ml min-1⋅kg-1/ 37.1 ± 13.2 ml min-1⋅kg-1) versus PLA (25.2 ± 3.7 ml min-1⋅kg-1/ 33.1 ± 5.3 ml min-1⋅kg-1) condition (p = 0.447/p = 0.756). During maximal exercise peak work load (PLA: 3.5 ± 0.6 W⋅kg-1 vs. EPO: 3.5 ± 0.6 W kg-1, p = 0.892) and peak oxygen uptake (PLA: 45.1 ± 10.4 ml⋅min-1 kg-1 vs. EPO: 46.1 ± 14.2 ml⋅min-1 kg-1, p = 0.344) reached comparable values in the two treatment conditions. Other cardiopulmonary variables (ventilation, cardiac output, heart rate) also reached similar levels in the two treatment conditions. An interaction effect was found between treatment condition and sex resulting in higher peak oxygen consumption (p = 0.048) and ventilation (p = 0.044) in EPO-treated males. In conclusion, in a carefully conducted study using placebo-controlled design the present data failed to support the hypothesis that a single high dose of EPO has a measurable impact on work capacity in healthy subjects.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

3 downloads since deposited on 07 Jan 2021
3 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Intensive Care Medicine
04 Faculty of Medicine > Center for Integrative Human Physiology
05 Vetsuisse Faculty > Institute of Veterinary Physiology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
Dewey Decimal Classification:570 Life sciences; biology
Scopus Subject Areas:Life Sciences > Physiology
Health Sciences > Physiology (medical)
Uncontrolled Keywords:Physiology (medical), Physiology
Language:English
Date:29 September 2020
Deposited On:07 Jan 2021 15:21
Last Modified:01 Feb 2021 16:09
Publisher:Frontiers Research Foundation
ISSN:1664-042X
OA Status:Gold
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.3389/fphys.2020.537389
PubMed ID:33117187
Project Information:
  • : FunderSNSF
  • : Grant ID320030_125013
  • : Project TitleEpo in brain and blood: controlling the hypoxic ventilatory response and maximal exercise performance

Download

Gold Open Access

Download PDF  'A single 60.000 IU dose of erythropoietin does not improve short-term aerobic exercise performance in healthy subjects: a randomized, double-blind, placebo-controlled crossover trial'.
Preview
Content: Published Version
Language: English
Filetype: PDF
Size: 4MB
View at publisher
Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)